How MEF2D Affects Sorafenib Resistance in Liver Cancer
Author Information
Author(s): Li Xue, Chen Shimin, Shi Yuanyuan, Wang Yuanjing, Wang Xuanzhe, Lin Qian, Wu Chao, Fang Wenshuo, Sun Peng, Ma Leina
Primary Institution: Qingdao University
Hypothesis
Does the transcription factor MEF2D regulate the expression of ACSL3 and influence sorafenib resistance in hepatocellular carcinoma (HCC)?
Conclusion
The study found that MEF2D regulates ACSL3 expression, which in turn mediates sorafenib resistance by inhibiting ferroptosis in HCC.
Supporting Evidence
- ACSL3 was found to be aberrantly expressed in HCC and promoted the progression from NAFLD to HCC.
- Elevated ACSL3 expression inhibited ferroptosis and enhanced resistance to sorafenib.
- MEF2D directly regulated the upregulation of ACSL3 expression.
Takeaway
This study shows that a protein called MEF2D helps another protein, ACSL3, to protect liver cancer cells from a drug called sorafenib, making the cancer harder to treat.
Methodology
The study analyzed ACSL3 expression in HCC tissues and cell lines, assessed ferroptosis levels in ACSL3-silenced cells treated with sorafenib, and evaluated the regulatory relationship between MEF2D and ACSL3 using promoter binding assays.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website